Observational studyArquivos de gastroenterologia2025
SMOKING IMPACTS HELICOBACTER PYLORI ERADICATION: RESULTS FROM A BRAZILIAN UNIVERSITY HOSPITAL.
Observational study in Arquivos de gastroenterologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHelicobacter pylori infection has a high prevalence in Brazil, and eradication therapy is recommended for all diagnosed cases. While smoking has been identified as a factor associated with therapeutic failure, its impact on treatment efficacy has not yet been conclusively demonstrated in studies conducted within the Brazilian population.
objectiveTo determine the factors associated with Helicobacter pylori eradication failure in patients submitted to empirical 14-day antimicrobial therapy with omeprazole 20 mg BID, amoxicillin 1 g BID, and clarithromycin 500 mg BID at a Brazilian university center.
methodsAn observational and retrospective study was conducted in the Hospital de Clinicas, University of Campinas, Brazil, between April 2022 and September 2023. The study included treatment-naive patients with Helicobacter pylori infection. These patients received PPI-clarithromycin triple therapy and underwent the 13C-urea breath test (13C-UBT) to evaluate eradication. Clinical and demographic variables were analyzed as potential factors associated with therapeutic failure, including age, gender, obesity, diabetes mellitus, anxiety and depression disorders, irritable bowel syndrome, fibromyalgia, smoking, alcoholism and cirrhosis.
resultsA total of 97 patients were included, with a mean age of 55±14 years, 67 (69.1%) female. The antimicrobial treatment achieved 90.7% effectiveness (n=88). Smoking (P=0.0068) was the only factor associated with eradication failure after multiple regression analysis.
conclusionSmoking was the only factor associated with Helicobacter pylori eradication failure, as determined by the 13C-urea breath test.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.